Зрительные нарушения и болезнь Альцгеймера


А.Н. Боголепова (1), Е.В. Махнович (1), А.Н. Журавлева (2), Т.А. Донских (3)

1) ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; 2) ФГБОУ «Московский научно-исследовательский институт глазных болезней им. Гельмгольца» Минздрава России, Москва; 3) ГБУЗ «Городская поликлиника 212» ДЗ Москвы, Москва
В данной статье представлен аналитический обзор о возможных перспективах диагностики болезни Альцгеймера (БА) с помощью оптической когерентной томографии. Актуальность этой проблемы определяется неуклонным ростом численности больных, страдающих деменцией, у которых 60–80% случаев деменции обусловлены БА. Приводятся данные о структурных и функциональных изменениях в зрительном анализаторе при БА. В качестве актуальной рассматривается проблема доклинической диагностики БА с помощью оптической когерентной томографии (ОКТ). ОКТ – неинвазивный метод прижизненного исследования, с помощью которого получают изображение поперечного среза исследуемой ткани. Имеющиеся в литературе данные трактуют параметры ОКТ сетчатки как потенциальный биомаркер ранней стадии БА.

Литература


1. Alzheimer’s Association. 2017 Alzheimer’s Disease Factsand Figures. Alzheimers Dement 2017;13:325–73.

2. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid ß deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet. Neurol. 2013:12(4):357–67.

3. Reiman E.M., Quiroz Y.T., Fleisher A.S., Chen K., Velez-Pardos C., Jimenez-Del-Rio M., et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease in the presenilin 1 E280A kindred: A case-control study. Lancet. Neurol. 2012:11(2):1048–56.

4. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med. 2012;367(9):795–804.

5. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1133–42.

6. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004;256(3):183–94.

7. Kesler A., Vakhapova V., Korczyn A.D., Naftaliev E., Neudorfer M. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. Clin. Neurol. Neurosurg. 2011;113(7):523–26.

8. Risacher S.L., Wudunn D., Pepin S.M., MaGee T.R., McDonald B.C., Flashman L.A., et al. Visual contrast sensitivity in Alzheimer’s disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiol. Aging.2013;34(4):1133–44.

9. Cunha J.P., Moura-Coelho N.., Proença R.P., Dias-Santos A., Ferreira J., Louro C., Castanheira-Dinis A. Alzheimer’s disease: A review of its visual system neuropathology. Optical coherence tomography- a potential role as a study tool in vivo. Graefes Arch. Clin. Exp. Ophthalmol. 2016;254(11):2079–92.

10. Polo V., Rodrigo M.J., Garcia-Martin E., Otin S., Larrosa J.M., Fuertes M.I., Bambo M.P., Pablo L.E., Satue M. Visual dysfunction and its correlation with retinal changes in patients with Alzheimer’s disease. Eye (Lond). 2017 Mar 10.

11. McKee A.C., Au R., Cabral H.J., Kowall N.W., Seshadri S., Kubilus C.A., et al. Visual association pathology in preclinical Alzheimer disease. J. Neuropathol. Exp. Neurol. 2006;65(6):621–30.

12. Hinton D.R., Sadun A.A., Blanks J.C., Miller C.A. Optic-nerve degeneration in Alzheimer’s disease. N. Engl. J. Med. 1986;315(8):485–87.

13. Sadun A.A., Bassi C.J. Optic nerve damage in Alzheimer’s disease. Ophthalmology. 1990;97(1):9–17.

14. Berisha F., Feke G.T., Trempe C.L., McMeel J.W., Schepens C.L. Retinal abnormalities in early Alzheimer’s disease. Invest. Ophthalmol. Vis. Sci. 2007;48(5):2285–89.

15. Bambo M.P., Garcia-Martin E., Gutierrez-Ruiz F., Pinilla J., Perez-Olivan S., Larrosa J.M., Polo V., Pablo L. Analysis of optic disk color changes in Alzheimer’s disease: a potential new biomarker. Clin. Neurol. Neurosurg. 2015;132:68–73.

16. Grunberger J., Linzmayer L., Walter H., Rainer M., Masching A., Pezawas L., et al. Receptor test (pupillary dilatation after application of 0,01% tropicamide solution) and determination of central nervous activation (Fourier analysis of papillary oscillations) in patients with Alzheimer’s disease. Neuropsychobiology. 1999;40(1):40–6.

17. Iijima A., Haida M., Ishikawa N., Ueno A., Minamitani H., Shinohara Y. Re-evaluation of tropicamide in the papillary response test for Alzheimer’s disease. Neurobiol. Aging. 2003;4(6):789–96.

18. Scinto L.F., Daffner K.R., Dressler D., Ransil B.I., Rentz D., Weintraub S., et al. A potential noninvasive neurobiological test for Alzheimer’s disease. Science. 1994;266(5187):1051–54.

19. Idiaquez J., Alvarez G., Villagra R., San Martin R.A. Cholinergic supersensitivity of the iris in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 1994;57(12):1544–45.

20. Fotiou D.F., Brozou C.G., Haidich A.B., Tsiptsios D., Nakou M., Kabitsi A., et al. Pupil reaction to light in Alzheimer’s disease: evaluation of pupil size changes and mobility. Aging. Clin. Exp. Res. 200719(5):364–71.

21. Fotiou F., Fountoulakis K.N., Tsolaki M., Goulas A., Palikaras A. Changes in pupil reaction to light in Alzheimer’s disease patients: a preliminary report. Int. J. Psychophysiol. 2000;37(1):111–20.

22. Heaton G.R., Davis B.M., Turner L.A., Cordeiro M.F. Ocular biomarkers of Alzheimer’s disease. Cent. Nerv. Syst. Agents. Med. Chem. 2015;15(2):117–25.

23. Cheung C.Y., Ikram M.K., Chen C., Wong T.Y. Imaging retina to study dementia and stroke. Prog. Retin. Eye Res. 2017;57:89–107.

24. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006;20:6–15.

25. Alexandrov P.N., Pogue A., Bhattacharjee S., Lukiw W.J. Retinal amyloid peptides and complement factor H in transgenic models of Alzheimer’s disease. Neuroreport. 2011;22:623–27.

26. Dutescu R.M., Li Q.X., Crowston J., Masters C.L., Baird P.N., Culvenor J.G. Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer’s disease. Graefes Arch. Clin. Exp. Ophthalmol. 2009;247:1213–21.

27. Kayabasi U., Sergott R., Rispoli M. Retinal examination for the diagnosis of Alzheimer’s disease. Int. J. Ophthamalic. Pathol. 2014;3:4–7.

28. Goldstein L.E., Muffat J.A., Cherny R.A., Moir R.D., Ericsson M.H., Huang X., et al. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer’s disease. Lancet. 2003;361(9365):1258–65.

29. Frost S., Kanagasingam Y., Sohrabi H., Vignarajan J., Bourgeat P., Salvado O., Villemagne V., Rowe C.C., Lance Macaulay S., Szoeke C., Ellis K.A., Ames D., Masters C.L., Rainey-Smith S., Martins R.N. and the AIBL Research Group Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease. Translational Psychiatry. 2013;3:e233. Doi:10.1038/tp.2012.150.

30. Ho C.Y., Troncoso J.C., Knox D., Stark W., Eberhart C.G. Beta-amyloid, phospho-tau, and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer’s and Parkinson’s disease patients. Brain Pathol. 2014;24:25–32.

31. Schon C., Hoffman N.A., Ochs S.M., Burgold S., Filser S., Steinbach S., et al. Long-term in-vivo imaging of fibrillary tau in the retina of P310S transgenic mice. PLoS One. 2012;7:e53547.

32. Gupta V., Gupta V.B., Chitranshi N., Gangoda S., VanderWall R., Abbasi M., Golzan M., Dheer Y., Shah T., Avolio A., Chung R., Martins R., Graham S. One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina. Cell. Mol. Life Sci. 2016;73(22):4279–97.

33. Tamura H., Kawakami H., Kanamoto T., Kato T., Yokoyama T., Sasaki K., et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer’s disease. J. Neurol. Sci. 2006;246:79–83.

34. Danesh-Meyer H.V., Birch H., Ku J.Y., Carroll S., Gamble G. Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology. 2006;67:1852–54.

35. Parisi V., Restuccia R., Fattapposta F., Mina C., Bucci M.G., Pierelli F. Morphological and functional retinal impairment in Alzheimer’s disease patients. Clin. Neurophysiol. 2001;112:1860–67.

36. Paquet C., Boissonnot M., Roger F., Dighiero P., Gil R., Hugon J. Abnormal retinal thickness inpatients with mild cognitive impairment and Alzheimer’s disease. Neurosci. Lett. 2007;420:97–9.

37. Gao L., Liu Y., Li X., Bai Q., Liu P. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer’s disease. Arch. Gerontol. Geriatr. 2015;60(1):162–67.

38. Moschos M.M., Markopoulos I., Chatziralli I., Rouvas A., Papageorgiou S.G., Ladas I., Vassilopoulos D. Structural and functional impairment of the retina and optic nerve in Alzheimer’s disease. Curr. Alzheimer Res. 2012;9(7):782–88.

39. Iseri P.K., Altinas O., Tokay T., Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J. Neuroophthalmol. 2006;26:18–24.

40. Liu S., Ong Y.T., Hilal S., Loke Y.M., Wong T.Y., Chen C.L., Cheung C.Y., Zhou J. The Association Between Retinal Neuronal Layer and Brain Structure is Disrupted in Patients with Cognitive Impairment and Alzheimer’s Disease. J. Alzheimers Dis. 2016;54(2):585–95.

41. Cunha L.P., Lopes L.C., Costa-Cunha L.V.F., Costa C.F., Pires L.A., Almeida A.L.M., et al. Macular Thickness Measurements with Frequency Domain-OCT for Quantification of Retinal Neural Loss and its Correlation with Cognitive Impairment in Alzheimerʼs Disease. PLoS ONE. 2016;11(4):e0153830.

42. Blanks J.C., Torigoe Y., Hinton D.R., Blanks R.H. Retinal pathology in Alzheimer’s disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol. Aging. 1996;17:377–384.

43. Güneş A., Demirci S., Tök L., Tök Ö., Demirci S. Evaluation of retinal nerve fiber layer thickness in Alzheimer disease using spectral-domain optical coherence tomography. Turk. J. Med. Sci. 2015;45(5):1094–97.

44. Shi Z., Zhu Y., Wang M., Wu Y., Cao J., Li C., Xie Z., Shen Y. The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration. J. Alzheimers Dis. 2016;49(2):399–405.

45. Marziani E., Pomati S., Ramolfo P., Cigada M., Giani A., Mariani C., Staurenghi G. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer’s disease using spectral-domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 2013;54(9):5953–58.

46. Gimenez-Castejon D., Gomez-Gallego M., Martinez-Martinez M.L., Dudekova M., Lajara-Blesa J. How far reaches earliness of optical coherence tomography in cognitive impairment. Rev. Neurol. 2016;63(1):5–10.

47. Ascaso F.J., Cruz N., Modrego P.J., Lopez-Anton R., Santabárbara J., Pascual LF., Lobo A., Cristóbal J.A. Retinal alterations in mild cognitive impairment and Alzheimer’s disease: an optical coherence tomography study. J. Neurol. 2014;261(8):1522–30.

48. Shen Y., Liu L., Cheng Y., Feng W., Shi Z., Zhu Y., Wu W., Li C. Retinal nerve fiber layer thickness is associated with episodic memory deficit in mild cognitive impairment patients. Curr. Alzheimer Res. 2014;11(3):259–66.

49. Parisi V. Correlation between morphological and functional retinal impairment in patients affected by ocular hypertension, glaucoma, demyelinating optic neuritis and Alzheimer’s disease. Semin. Ophthalmol. 2003;18:50–7.

50. Larrosa J.M., Garcia-Martin E., Bambo M.P., Pinilla J., Polo V., Otin S., et al. Potential new diagnostic tool for Alzheimer’s disease using a linear discriminant function for Fourier domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 2014;55:3043–51.

51. Lu Y., Li Z., Zhang X., Ming B., Jia J., Wang R., Ma D. Retinal nerve fiber layer structure abnormalities in early Alzheimer’s disease: evidence in optical coherence tomography. Neurosci Lett. 2010;480(1):69–72.

52. Kirbas S, Turkyilmaz K, Anlar O, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J. Neuroophthalmol. 2013;33:58–61.

53. Kromer R., Serbecic N., Hausner L., Froelich L., Aboul-Enein F., Beutelspacher S.C. Detection of Retinal Nerve Fiber Layer Defects in Alzheimer’s Disease Using SD-OCT. Front. Psychiatry. 2014;5:22.

54. Coppola G., DiRenzo A., Ziccardi L., Martelli F., Fadda A., Manni G., et al. Optical Coherence Tomography in Alzheimer’s Disease: A Meta-Analysis. PLoS ONE. 2015;10(8):e0134750.

55. van Koolwijk L.M., Despriet D.D., Van Duijn C.M., Oostra B.A., van Swieten J.C., de Koning I., et al. Association of cognitive functioning with retinal nerve fiber layer thickness. Invest. Ophthalmol. Vis. Sci 2009;50(10):4576–80.

56. Shi Z., Wu Y., Wang M., Cao J., Feng W., Cheng Y., Li C., ShenY. Greater attenuation of retinal nerve fiber layer thickness in Alzheimer’s disease patients. J. Alzheimers Dis. 2014;40(2):277–83. doi: 10.3233/JAD-131898.

57. Eraslan M., Çerman E., Çekiç O., Balci S., Dericioğlu V., Sahin Ö., Süer D., Chabou B., Tuncer Elmaci E.N. Neurodegeneration in ocular and central nervous systems: optical coherence tomography study in normal-tension glaucoma and Alzheimer disease. Turk. J. Med. Sci. 2015;45(5):1106–14.

58. Cheung C.Y., Ong Y.T., Hilal S., Ikram M.K., Low S., Ong Y.L., Venketasubramanian N., Yap P., Seow D., Chen C.L., Wong T.Y. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer’s disease. J. Alzheimers Dis. 2015;45(1):45–56.

59. Turski G.N., Schmitz-Valckenberg S., Holz F.G., Finger R.P. Retinal imaging of the macula and optic disc in neurodegenerative diseases. Ophthalmologe. 2017;114(2):114–19.


Об авторах / Для корреспонденции


Автор для связи: А.Н. Боголепова – д.м.н., проф. кафедры неврологии, нейрохирургии и медицинской генетики лечебного факультета ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, Москва; e-mail: annabogolepova@yandex.ru


Похожие статьи


Бионика Медиа